Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	extracellular matrix structural constituent conferring compression resistance	HSPG2 ACAN	6.56e-04	23	33	2	GO:0030021
GeneOntologyMolecularFunction	extracellular matrix structural constituent	HSPG2 COL7A1 ACAN	3.64e-03	188	33	3	GO:0005201
GeneOntologyCellularComponent	basement membrane	HSPG2 COL7A1 RELL2 ACAN	3.96e-05	122	33	4	GO:0005604
GeneOntologyCellularComponent	Golgi lumen	MUC19 HSPG2 ACAN	6.71e-04	109	33	3	GO:0005796
HumanPheno	Blepharospasm	HSPG2 PANK2 ATN1	6.83e-05	36	12	3	HP:0000643
HumanPheno	Abnormal eyelid physiology	HSPG2 PANK2 ATN1	8.71e-05	39	12	3	HP:0031879
HumanPheno	Abnormal ocular adnexa physiology	HSPG2 PANK2 ATN1	8.71e-05	39	12	3	HP:0032040
Domain	Guanylate_kin	CACNB1 DLG5	8.45e-04	26	31	2	PF00625
Domain	GK/Ca_channel_bsu	CACNB1 DLG5	8.45e-04	26	31	2	IPR008145
Domain	Guanylate_kin-like_dom	CACNB1 DLG5	8.45e-04	26	31	2	IPR008144
Domain	GuKc	CACNB1 DLG5	8.45e-04	26	31	2	SM00072
Domain	KH_1	ANKRD17 KHDRBS1	1.81e-03	38	31	2	PF00013
Domain	-	ANKRD17 KHDRBS1	1.90e-03	39	31	2	3.30.1370.10
Domain	KH	ANKRD17 KHDRBS1	2.00e-03	40	31	2	SM00322
Domain	KH_dom	ANKRD17 KHDRBS1	2.00e-03	40	31	2	IPR004087
Domain	KH_TYPE_1	ANKRD17 KHDRBS1	2.20e-03	42	31	2	PS50084
Domain	KH_dom_type_1	ANKRD17 KHDRBS1	2.42e-03	44	31	2	IPR004088
Domain	SH3	CACNB1 DLG5 ABL2	5.40e-03	216	31	3	PS50002
Domain	SH3	CACNB1 DLG5 ABL2	5.40e-03	216	31	3	SM00326
Domain	SH3_domain	CACNB1 DLG5 ABL2	5.68e-03	220	31	3	IPR001452
Domain	-	PDS5A HGH1 NEK10	5.83e-03	222	31	3	1.25.10.10
Domain	ARM-like	PDS5A HGH1 NEK10	9.96e-03	270	31	3	IPR011989
Domain	PROTEIN_KINASE_TYR	ABL2 NEK10	1.13e-02	97	31	2	PS00109
Domain	Tyr_kinase_AS	ABL2 NEK10	1.13e-02	97	31	2	IPR008266
Pubmed	Spatiotemporal profile of postsynaptic interactomes integrates components of complex brain disorders.	ANKRD17 DIP2B CACNB1 FAM120A NEDD4L NHSL2 PRRC2A KIAA1217	2.52e-06	963	33	8	28671696
Pubmed	Topographical variation in the distributions of versican, aggrecan and perlecan in the foetal human spine reflects their diverse functional roles in spinal development.	HSPG2 ACAN	2.62e-06	3	33	2	19669783
Pubmed	An in situ hybridization study of perlecan, DMP1, and MEPE in developing condylar cartilage of the fetal mouse mandible and limb bud cartilage.	HSPG2 ACAN	5.23e-06	4	33	2	26428891
Pubmed	Interactome of vertebrate GAF/ThPOK reveals its diverse functions in gene regulation and DNA repair.	ANKRD17 DIP2B FAM120A KHDRBS1 PRRC2A	1.25e-05	321	33	5	32098917
Pubmed	Over-expression of the chondroitin sulphate proteoglycan versican is associated with defective neural crest migration in the Pax3 mutant mouse (splotch).	HSPG2 ACAN	1.31e-05	6	33	2	9486530
Pubmed	A central chaperone-like role for 14-3-3 proteins in human cells.	ANKRD17 DIP2B DLG5 PANK2 ABL2 NEDD4L KIAA1217	1.35e-05	861	33	7	36931259
Pubmed	Elucidation of the BMI1 interactome identifies novel regulatory roles in glioblastoma.	DIP2B DLG5 FAM120A KHDRBS1 PRRC2A	1.40e-05	329	33	5	34316702
Pubmed	Qualitative and quantitative analyses of protein phosphorylation in naive and stimulated mouse synaptosomal preparations.	PALM CACNB1 ABL2 NEDD4L PRRC2A	1.81e-05	347	33	5	17114649
Pubmed	Perlecan is essential for cartilage and cephalic development.	HSPG2 ACAN	3.13e-05	9	33	2	10545953
Pubmed	Dynamic expression patterns of ECM molecules in the developing mouse olfactory pathway.	HSPG2 ACAN	3.13e-05	9	33	2	18570250
Pubmed	Lethal skeletal dysplasia in mice and humans lacking the golgin GMAP-210.	HSPG2 ACAN	3.91e-05	10	33	2	20089971
Pubmed	Inflammasome activation and metabolic remodelling in p16-positive aging cells aggravates high-fat diet-induced lung fibrosis by inhibiting NEDD4L-mediated K48-polyubiquitin-dependent degradation of SGK1.	ABL2 NEDD4L	3.91e-05	10	33	2	37345264
Pubmed	Comparison of substrate specificity of the ubiquitin ligases Nedd4 and Nedd4-2 using proteome arrays.	CACNB1 ABL2 NEDD4L ACAN	4.04e-05	203	33	4	19953087
Pubmed	Human transcription factor protein interaction networks.	ANKRD17 HSPG2 PDS5A FAM120A ATN1 KHDRBS1 PRRC2A ZFP91	4.41e-05	1429	33	8	35140242
Pubmed	BioID-based intact cell interactome of the Kv1.3 potassium channel identifies a Kv1.3-STAT3-p53 cellular signaling pathway.	ANKRD17 PDS5A MCM4 DLG5 ABL2 PRRC2A	4.83e-05	708	33	6	39231216
Pubmed	Competitive binding of E3 ligases TRIM26 and WWP2 controls SOX2 in glioblastoma.	BLVRB ANKRD17 DLG5 KHDRBS1 KIAA1217 NCCRP1	5.81e-05	732	33	6	34732716
Pubmed	Transcriptome-based systematic identification of extracellular matrix proteins.	HSPG2 COL7A1 RELL2	5.86e-05	79	33	3	18757743
Pubmed	Global landscape of HIV-human protein complexes.	ANKRD17 MCM4 NEDD4L HGH1 ZFP91	6.71e-05	457	33	5	22190034
Pubmed	A systems-wide screen identifies substrates of the SCFβTrCP ubiquitin ligase.	MCM4 FAM120A KHDRBS1 PRRC2A	6.78e-05	232	33	4	25515538
Pubmed	A developmental transcriptomic analysis of Pax1 and Pax9 in embryonic intervertebral disc development.	HSPG2 ACAN	7.89e-05	14	33	2	28011632
Pubmed	Large-scale characterization of HeLa cell nuclear phosphoproteins.	ANKRD17 DIP2B MCM4 ATN1 PRRC2A ZFP91	7.90e-05	774	33	6	15302935
Pubmed	Perlecan maintains the integrity of cartilage and some basement membranes.	HSPG2 ACAN	9.10e-05	15	33	2	10579729
Pubmed	Human Antiviral Protein IFIX Suppresses Viral Gene Expression during Herpes Simplex Virus 1 (HSV-1) Infection and Is Counteracted by Virus-induced Proteasomal Degradation.	ANKRD17 HSPG2 FAM120A KHDRBS1	9.19e-05	251	33	4	28077445
Pubmed	Sox5 and Sox6 are required for notochord extracellular matrix sheath formation, notochord cell survival and development of the nucleus pulposus of intervertebral discs.	HSPG2 ACAN	1.32e-04	18	33	2	12571105
Pubmed	Genetic and Proteomic Interrogation of Lower Confidence Candidate Genes Reveals Signaling Networks in β-Catenin-Active Cancers.	ANKRD17 MCM4 DLG5 FAM120A ATN1 KHDRBS1 PRRC2A	1.41e-04	1247	33	7	27684187
Pubmed	PDGFRβ regulates craniofacial development through homodimers and functional heterodimers with PDGFRα.	HSPG2 COL7A1	1.81e-04	21	33	2	27856617
Pubmed	EG-1 interacts with c-Src and activates its signaling pathway.	ABL2 NEDD4L	1.99e-04	22	33	2	16964398
Pubmed	TBK1 phosphorylation activates LIR-dependent degradation of the inflammation repressor TNIP1.	MCM4 DLG5 FAM120A KHDRBS1 NCCRP1 ZFP91	2.40e-04	949	33	6	36574265
Pubmed	HDLBP Promotes Hepatocellular Carcinoma Proliferation and Sorafenib Resistance by Suppressing Trim71-dependent RAF1 Degradation.	BLVRB ANKRD17 DLG5 FAM120A NEDD4L PRRC2A ZFP91	2.53e-04	1371	33	7	36244648
Pubmed	Cellular localization and characterization of cytosolic binding partners for Gla domain-containing proteins PRRG4 and PRRG2.	ABL2 NEDD4L	2.58e-04	25	33	2	23873930
Pubmed	Chondromodulin I is dispensable during enchondral ossification and eye development.	HSPG2 ACAN	3.02e-04	27	33	2	12192060
Pubmed	LCP1 preferentially binds clasped αMβ2 integrin and attenuates leukocyte adhesion under flow.	BLVRB DIP2B MCM4 FAM120A	3.07e-04	344	33	4	30333137
Pubmed	Basement membrane assembly of the integrin α8β1 ligand nephronectin requires Fraser syndrome-associated proteins.	HSPG2 COL7A1	3.49e-04	29	33	2	22613833
Pubmed	Functional proteomics establishes the interaction of SIRT7 with chromatin remodeling complexes and expands its role in regulation of RNA polymerase I transcription.	ANKRD17 PDS5A MCM4 FAM120A PRRC2A	3.53e-04	653	33	5	22586326
Pubmed	MKRN2 Physically Interacts with GLE1 to Regulate mRNA Export and Zebrafish Retinal Development.	MCM4 PANK2 NEDD4L KHDRBS1	3.57e-04	358	33	4	32460013
Pubmed	The PRMT5/WDR77 complex regulates alternative splicing through ZNF326 in breast cancer.	FAM120A KHDRBS1 PRRC2A	3.68e-04	147	33	3	28977470
Pubmed	Identifying and quantifying in vivo methylation sites by heavy methyl SILAC.	FAM120A KHDRBS1	3.74e-04	30	33	2	15782174
Pubmed	A quantitative chaperone interaction network reveals the architecture of cellular protein homeostasis pathways.	MCM4 DLG5 ABL2 HGH1	3.76e-04	363	33	4	25036637
Pubmed	The RNA-mediated estrogen receptor α interactome of hormone-dependent human breast cancer cell nuclei.	BLVRB ANKRD17 PDS5A DLG5 TBC1D30 PRRC2A ZFP91	4.31e-04	1497	33	7	31527615
Pubmed	Post-entrapment genome engineering: first exon size does not affect the expression of fusion transcripts generated by gene entrapment.	PANK2 KHDRBS1	4.81e-04	34	33	2	15741512
Pubmed	The spatiotemporal expression pattern of Syndecans in murine embryonic teeth.	HSPG2 ACAN	4.81e-04	34	33	2	32220631
Pubmed	Laminin-511 is an epithelial message promoting dermal papilla development and function during early hair morphogenesis.	HSPG2 COL7A1	5.09e-04	35	33	2	18676816
Pubmed	WDR76 Co-Localizes with Heterochromatin Related Proteins and Rapidly Responds to DNA Damage.	PDS5A MCM4 PRRC2A ZFP91	5.12e-04	394	33	4	27248496
Pubmed	ARMC5 is part of an RPB1-specific ubiquitin ligase implicated in adrenal hyperplasia.	BLVRB MCM4 KHDRBS1	5.24e-04	166	33	3	35687106
Pubmed	PRISMA and BioID disclose a motifs-based interactome of the intrinsically disordered transcription factor C/EBPα.	PDS5A MCM4 FAM120A KHDRBS1 PRRC2A ZFP91	5.34e-04	1103	33	6	34189442
Pubmed	Mapping the MOB proteins' proximity network reveals a unique interaction between human MOB3C and the RNase P complex.	PDS5A MCM4 DLG5 KHDRBS1	5.37e-04	399	33	4	37536630
Pubmed	Chondrocytes respond to an altered heparan sulfate composition with distinct changes of heparan sulfate structure and increased levels of chondroitin sulfate.	HSPG2 ACAN	5.69e-04	37	33	2	32201365
Pubmed	Control of cardiac jelly dynamics by NOTCH1 and NRG1 defines the building plan for trabeculation.	HSPG2 ACAN	6.01e-04	38	33	2	29743679
Pubmed	Fgf and Esrrb integrate epigenetic and transcriptional networks that regulate self-renewal of trophoblast stem cells.	PDS5A MCM4 KIAA1217	6.32e-04	177	33	3	26206133
Pubmed	A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2-Bispecific Antibody for Combination Cancer Therapy.	PALM ABL2 NEDD4L KIAA1217	6.56e-04	421	33	4	36976175
Pubmed	Tumor suppressor BAP1 nuclear import is governed by transportin-1.	ANKRD17 PDS5A MCM4 FAM120A KHDRBS1 PRRC2A	6.61e-04	1149	33	6	35446349
Pubmed	Analysis of the Histone H3.1 Interactome: A Suitable Chaperone for the Right Event.	MCM4 KHDRBS1 PRRC2A	6.85e-04	182	33	3	26527279
Pubmed	Defining the membrane proteome of NK cells.	ANKRD17 DIP2B MCM4 FAM120A KHDRBS1 PRRC2A	7.21e-04	1168	33	6	19946888
Pubmed	Mechanistic insights into COVID-19 by global analysis of the SARS-CoV-2 3CLpro substrate degradome.	MCM4 PRRC2A	7.69e-04	43	33	2	34672947
Pubmed	New roles for the de-ubiquitylating enzyme OTUD4 in an RNA-protein network and RNA granules.	ANKRD17 FAM120A KHDRBS1 PRRC2A	9.27e-04	462	33	4	31138677
Interaction	NCK2 interactions	ABL2 ATN1 KHDRBS1 NHSL2 PRRC2A KIAA1217	3.76e-06	262	33	6	int:NCK2
Interaction	CACNB1 interactions	CACNB1 ATN1 NEDD4L	8.98e-06	25	33	3	int:CACNB1
GeneFamily	Calcium voltage-gated channel subunits\|Membrane associated guanylate kinases	CACNB1 DLG5	3.00e-04	26	18	2	904
GeneFamily	Immunoglobulin like domain containing	HSPG2 ADGRA2	1.55e-02	193	18	2	594
ToppCell	normal_Lung-Fibroblasts-Myofibroblasts\|Fibroblasts / Location, Cell class and cell subclass	COL7A1 ACAN KIAA1217 APCDD1L	6.41e-06	164	33	4	9b4a6007abae992db871d9f6f731d5af724de30d
ToppCell	TCGA-Prostate-Primary_Tumor-Prostate_Adenocarcinoma-Acinar_Adenocarcinoma-6\|TCGA-Prostate / Sample_Type by Project: Shred V9	DIP2B PDS5A FAM120A ZFP91	1.22e-05	193	33	4	abd71b2cf667ef2b1c4d88acd0c1dd19a12ff659
Drug	Deltaline [6836-11-9]; Up 200; 7.8uM; PC3; HT_HG-U133A	HSPG2 CACNB1 NDUFAF5 ATN1 TBC1D30 ACAN	3.14e-07	193	33	6	4306_UP
Drug	S(-)Eticlopride hydrochloride [97612-24-3]; Up 200; 10.6uM; MCF7; HT_HG-U133A	PALM CACNB1 ATN1 KHDRBS1 ADGRA2 ACAN	3.65e-07	198	33	6	3393_UP
Drug	Norgestrel-(-)-D [797-63-7]; Up 200; 12.8uM; PC3; HT_HG-U133A	PALM ATN1 ADGRA2 ACAN RNF146	8.13e-06	193	33	5	3708_UP
Drug	Fluvoxamine maleate [61718-82-9]; Up 200; 9.2uM; MCF7; HT_HG-U133A	PALM HSPG2 CACNB1 ATN1 ADGRA2	8.76e-06	196	33	5	4114_UP
Drug	Cefotaxime sodium salt [64485-93-4]; Up 200; 8.4uM; PC3; HT_HG-U133A	PALM HSPG2 COL7A1 NDUFAF5 TBC1D30	8.76e-06	196	33	5	2072_UP
Drug	Amiloride hydrochloride dihydrate [17440-83-4]; Down 200; 13.2uM; PC3; HT_HG-U133A	DLG5 ABL2 ATN1 TBC1D30 PRRC2A	9.21e-06	198	33	5	3990_DN
Drug	Molsidomine [25717-80-0]; Up 200; 16.6uM; HL60; HG-U133A	PALM CACNB1 ABL2 TBC1D30 ACAN	9.21e-06	198	33	5	1711_UP
Drug	Sulpiride [15676-16-1]; Up 200; 11.8uM; MCF7; HT_HG-U133A	PALM COL7A1 CACNB1 NDUFAF5 ACAN	9.43e-06	199	33	5	4389_UP
Drug	neol	HSPG2 ATN1	1.33e-04	12	33	2	CID000031344
Drug	Sm25	ATN1 ACAN	1.33e-04	12	33	2	CID000486046
Drug	LY 294002; Down 200; 10uM; HL60; HT_HG-U133A	COL7A1 CACNB1 TBC1D30 ADGRA2	1.53e-04	188	33	4	6195_DN
Drug	Mepenzolate bromide [76-90-4]; Up 200; 9.6uM; PC3; HT_HG-U133A	PALM HSPG2 NDUFAF5 ATN1	1.56e-04	189	33	4	4304_UP
Drug	poly(3-hydroxybutyrate-co-3-hydroxyvalerate	HSPG2 ACAN	1.57e-04	13	33	2	CID000107801
Drug	Meclofenoxate hydrochloride [3685-84-5]; Up 200; 13.6uM; PC3; HT_HG-U133A	HSPG2 CACNB1 ATN1 TBC1D30	1.66e-04	192	33	4	4268_UP
Drug	Clozapine [5786-21-0]; Up 200; 12.2uM; PC3; HT_HG-U133A	DLG5 ABL2 ADGRA2 ACAN	1.69e-04	193	33	4	4670_UP
Drug	Carisoprodol [78-44-4]; Up 200; 15.4uM; MCF7; HT_HG-U133A	PALM ATN1 ADGRA2 ACAN	1.69e-04	193	33	4	3251_UP
Drug	Muramic acid, N-acetyl [10597-89-4]; Up 200; 13.6uM; MCF7; HT_HG-U133A	PALM HSPG2 ATN1 PRRC2A	1.69e-04	193	33	4	3262_UP
Drug	Sulfamethazine sodium salt [1981-58-4]; Up 200; 13.4uM; PC3; HT_HG-U133A	HSPG2 COL7A1 NEDD4L ADGRA2	1.69e-04	193	33	4	4322_UP
Drug	Dizocilpine maleate [77086-22-7]; Up 200; 11.8uM; PC3; HT_HG-U133A	HSPG2 PDS5A MCM4 RNF146	1.72e-04	194	33	4	2069_UP
Drug	Zardaverine [101975-10-4]; Up 200; 15uM; MCF7; HT_HG-U133A	ABL2 ATN1 TBC1D30 ACAN	1.72e-04	194	33	4	7347_UP
Drug	Dipyrone [5907-38-0]; Up 200; 12uM; PC3; HT_HG-U133A	PALM HSPG2 ATN1 TBC1D30	1.72e-04	194	33	4	4310_UP
Drug	Acetylsalicylsalicylic acid [530-75-6]; Up 200; 13.4uM; MCF7; HT_HG-U133A	COL7A1 CACNB1 ADGRA2 ACAN	1.72e-04	194	33	4	2223_UP
Drug	trifluoperazine dihydrochloride; Up 200; 10uM; HL60; HT_HG-U133A	COL7A1 CACNB1 ATN1 ACAN	1.76e-04	195	33	4	6183_UP
Drug	Harmaline hydrochloride dihydrate [6027-98-1]; Up 200; 14uM; MCF7; HT_HG-U133A	PALM HSPG2 CACNB1 ATN1	1.76e-04	195	33	4	2805_UP
Drug	Flumethasone [2135-17-3]; Up 200; 9.8uM; PC3; HT_HG-U133A	HSPG2 CACNB1 NDUFAF5 ATN1	1.76e-04	195	33	4	4272_UP
Drug	Alfaxalone [23930-19-0]; Up 200; 12uM; MCF7; HT_HG-U133A	ABL2 NDUFAF5 ATN1 ADGRA2	1.76e-04	195	33	4	5451_UP
Drug	Thiocolchicoside [602-41-5]; Up 200; 7uM; MCF7; HT_HG-U133A	HSPG2 ATN1 KHDRBS1 ADGRA2	1.76e-04	195	33	4	2875_UP
Drug	Trimethoprim [738-70-5]; Up 200; 13.8uM; PC3; HT_HG-U133A	TBC1D30 KHDRBS1 ADGRA2 ACAN	1.79e-04	196	33	4	3678_UP
Drug	Parbendazole [14255-87-9]; Up 200; 16.2uM; MCF7; HT_HG-U133A	PALM NDUFAF5 ATN1 ACAN	1.79e-04	196	33	4	4357_UP
Drug	Fludrocortisone acetate [514-36-3]; Up 200; 9.4uM; PC3; HT_HG-U133A	PALM COL7A1 TBC1D30 ADGRA2	1.79e-04	196	33	4	4342_UP
Drug	Hydrastine hydrochloride [5936-28-7]; Up 200; 9.6uM; MCF7; HT_HG-U133A	DLG5 ABL2 ATN1 NEDD4L	1.83e-04	197	33	4	2889_UP
Drug	LY294002; Down 200; 0.1uM; MCF7; HG-U133A	CACNB1 NEDD4L TBC1D30 ACAN	1.83e-04	197	33	4	424_DN
Drug	Cetirizine dihydrochloride [83881-52-1]; Up 200; 8.6uM; HL60; HT_HG-U133A	CACNB1 ATN1 NEDD4L ACAN	1.83e-04	197	33	4	2468_UP
Drug	Bromopride [4093-35-0]; Up 200; 11.6uM; PC3; HT_HG-U133A	COL7A1 CACNB1 ATN1 ACAN	1.83e-04	197	33	4	3719_UP
Drug	(+,-)-Synephrine [94-07-5]; Up 200; 24uM; PC3; HT_HG-U133A	PALM PDS5A COL7A1 CACNB1	1.83e-04	197	33	4	7150_UP
Drug	Foliosidine [2520-38-9]; Down 200; 13uM; PC3; HT_HG-U133A	PALM HSPG2 ATN1 NEDD4L	1.83e-04	197	33	4	4295_DN
Drug	Prilocaine hydrochloride [1786-81-8]; Up 200; 15.6uM; PC3; HT_HG-U133A	CACNB1 ADGRA2 ACAN RNF146	1.83e-04	197	33	4	3727_UP
Drug	prochlorperazine dimaleate salt; Down 200; 10uM; PC3; HT_HG-U133A	MCM4 DLG5 TBC1D30 PRRC2A	1.83e-04	197	33	4	1215_DN
Drug	Hydroxytacrine maleate (R,S) [118909-22-1]; Up 200; 12.2uM; PC3; HT_HG-U133A	CACNB1 ABL2 TBC1D30 ACAN	1.86e-04	198	33	4	6651_UP
Drug	Dilazep dihydrochloride [20153-98-4]; Up 200; 6uM; MCF7; HT_HG-U133A	COL7A1 CACNB1 ATN1 ADGRA2	1.86e-04	198	33	4	2294_UP
Drug	Pentamidine isethionate [140-64-7]; Up 200; 6.8uM; HL60; HT_HG-U133A	HSPG2 CACNB1 ABL2 ACAN	1.86e-04	198	33	4	2473_UP
Drug	Dantrolene sodium salt [14663-23-1]; Up 200; 11.8uM; PC3; HT_HG-U133A	COL7A1 TBC1D30 ADGRA2 ACAN	1.86e-04	198	33	4	4343_UP
Drug	Captopril [62571-86-2]; Up 200; 17.2uM; MCF7; HT_HG-U133A	PALM COL7A1 ADGRA2 ACAN	1.86e-04	198	33	4	4410_UP
Drug	sodium 4-phenylbutyrate; Up 200; 1000uM; PC3; HG-U133A	PDS5A CACNB1 KHDRBS1 ACAN	1.86e-04	198	33	4	434_UP
Drug	paclitaxel; Up 200; 0.1uM; MCF7; HG-U133A	CACNB1 ATN1 KHDRBS1 ACAN	1.86e-04	198	33	4	640_UP
Drug	Cefotiam hydrochloride; Up 200; 7.2uM; PC3; HT_HG-U133A	CACNB1 KHDRBS1 ADGRA2 ACAN	1.86e-04	198	33	4	6762_UP
Drug	Sulfadimethoxine [122-11-2]; Up 200; 12.8uM; HL60; HT_HG-U133A	COL7A1 ABL2 TBC1D30 ACAN	1.86e-04	198	33	4	2578_UP
Drug	PHA-00745360 [351320-33-7]; Up 200; 10uM; PC3; HT_HG-U133A	COL7A1 NDUFAF5 ATN1 ACAN	1.86e-04	198	33	4	3824_UP
Drug	Protoveratrine A [143-57-7]; Up 200; 5uM; PC3; HT_HG-U133A	PALM PDS5A KHDRBS1 ACAN	1.90e-04	199	33	4	6618_UP
Drug	0317956-0000 [391210-11-0]; Up 200; 10uM; PC3; HT_HG-U133A	CACNB1 NDUFAF5 ATN1 ACAN	1.90e-04	199	33	4	3774_UP
Drug	tolbutamide; Down 200; 100uM; MCF7; HG-U133A	PALM ABL2 TBC1D30 ACAN	1.90e-04	199	33	4	142_DN
Drug	0317956-0000 [391210-11-0]; Up 200; 1uM; PC3; HT_HG-U133A	CACNB1 NDUFAF5 ADGRA2 ACAN	1.90e-04	199	33	4	4334_UP
Drug	Perhexiline maleate [6724-53-4]; Up 200; 10.2uM; PC3; HT_HG-U133A	PALM ATN1 TBC1D30 ADGRA2	1.90e-04	199	33	4	5081_UP
Drug	N-Acetyl-L-leucine [1188-21-2]; Up 200; 23uM; MCF7; HT_HG-U133A	COL7A1 CACNB1 ABL2 KHDRBS1	1.94e-04	200	33	4	5683_UP
Disease	response to triptolide, cytotoxicity measurement	ADGRA2 NEK10	1.35e-04	16	32	2	EFO_0006952, EFO_0007662
Disease	protein-glutamine gamma-glutamyltransferase e measurement	DLG5 NEDD4L	1.94e-03	60	32	2	EFO_0020690
Disease	aspartate aminotransferase measurement	MUC19 DLG5 PANK2 NEDD4L PRRC2A	2.70e-03	904	32	5	EFO_0004736
Disease	Antihypertensive use measurement	DIP2B HSPG2 NEDD4L	2.93e-03	265	32	3	EFO_0009927
Disease	pyruvate measurement	NEDD4L ACAN KIAA1217	3.02e-03	268	32	3	EFO_0010117
Disease	Disproportionate short stature	HSPG2 ACAN	3.17e-03	77	32	2	C0878659

Protein segments in the cluster

Peptide	Gene	Start	Entry
SSSLGDVVTGTRRPT	CACNB1	191	Q02641
SGRRRDPAGRTTETG	ABL2	31	P42684
RRGVATPVIFAGTSG	ADGRA2	671	Q96PE1
ELRSRGRASPGGVST	ATN1	26	P54259
GAYTVTLDGRGPSRV	BLVRB	161	P30043
YTRGTPSTRVRGGTE	APCDD1L	336	Q8NCL9
SVPSTVISRVIGRGG	ANKRD17	1731	O75179
TRGAVEGAARTTPSR	PALM	256	O75781
PRVTVTSEGGRGTLI	HSPG2	451	P98160
TGRKPYVRSTGTETG	PDS5A	1151	Q29RF7
SSRVEGTPRSGVRGT	MCM4	96	P33991
PGGLRRTRVTDSSVS	NCCRP1	256	Q6ZVX7
SQTRDFTGGTGSRPR	NEK10	941	Q6ZWH5
GTTGPSVVRSGTTRL	MUC19	2211	Q7Z5P9
ARSGTGIPSVGETRT	MUC19	3591	Q7Z5P9
STRGVRTTGSEAPEG	MUC19	6286	Q7Z5P9
RIRATGSEAPGGTSR	MUC19	6361	Q7Z5P9
TGSTGGIRATRTEAP	MUC19	6536	Q7Z5P9
STRGVRTTRSEAPGG	MUC19	6646	Q7Z5P9
STRGVRTTRSEAPGE	MUC19	6736	Q7Z5P9
RYPRSVVGSERGSVS	DLG5	1281	Q8TDM6
GLSPRAVSTTFGSRV	DIP2B	1306	Q9P265
RGVISTPVIRTFGRG	FAM120A	986	Q9NZB2
SSPGVRTYGVRPSTE	ACAN	551	P16112
GTRRDRLGSYSGPTS	PANK2	181	Q9BZ23
VGVTRSSGTPRPGRE	FUT11	56	Q495W5
GTPVRGAITRGATVT	KHDRBS1	316	Q07666
YTVRVSARVGPREGS	COL7A1	571	Q02388
PDSSVRRGGVVGTLR	HGH1	211	Q9BTY7
PRTGETTVFSVGRFR	RELL2	156	Q8NC24
TSRLETGPGGASRFR	NHSL2	481	Q5HYW2
GPIGTERSQRTDRGT	PRRC2A	1731	P48634
GLTTTRSGDVVYTGR	KIAA1217	1061	Q5T5P2
AGGGTVSVSVRSRRP	RNF146	336	Q9NTX7
SVTGEGQGPRSRTFT	IL9R	41	Q01113
RREVTSGVSPRGSTS	NDUFAF5	26	Q5TEU4
AGREGSSPEGSTRRT	TBC1D30	781	Q9Y2I9
PAGTTSSRVLRGGRD	ZFP91	41	Q96JP5
GRARSSTVTGGEEPT	NEDD4L	361	Q96PU5